Literature DB >> 7298854

Abnormal high density lipoproteins in cerebrotendinous xanthomatosis.

V Shore, G Salen, F W Cheng, T Forte, S Shefer, G S Tint, F T Lindgren.   

Abstract

The plasma lipoprotein profiles and high density lipoproteins (HDL) were characterized in patients with the genetic disease cerebrotendinous xanthomatosis (CTX). Abnormalities in the HDL may contribute to their increased atherogenesis and excessive deposits of tissue sterols in the presence of low or low-normal concentrations of plasma cholesterol (165 +/- 25 mg/dl) and low density lipoproteins (LDL). The mean HDL-cholesterol concentration in the CTX plasmas was 14.5 +/- 3.2 mg/dl, about one-third the normal value. The low HDL-cholesterol reflects a low concentration and an abnormal lipid composition of the plasma HDL. Relative to normal HDL, the cholesteryl esters are low, free cholesterol and phospholipids essentially normal, and triglycerides increased. The ratio of apoprotein (apo) to total cholesterol in the HDL of CTX was two to three times greater than normal. In the CTX HDL, the ratio of apoAI to apoAII was high, the proportion of apoC low, and a normally minor form of apoAI increased relative to other forms. The HDL in electron micrographs appeared normal morphologically and in particle size. The abnormalities in lipoprotein distribution profile and composition of the plasma HDL result from metabolic defects that are not understood but may be linked to the genetic defect in bile acid synthesis in CTX. As a consequence, it is probable that the normal functions of the HDL, possibly including modulation of LDL-cholesterol uptake and the removal of excess cholesterol from peripheral tissues, are perturbed significantly in this disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298854      PMCID: PMC370925          DOI: 10.1172/jci110376

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  C-and N-terminal amino acids of human serum lipoproteins.

Authors:  B SHORE
Journal:  Arch Biochem Biophys       Date:  1957-09       Impact factor: 4.013

2.  Lecithin: cholesterol acyltransferase: effects of substrate composition upon enzyme activity.

Authors:  C J Fielding; V G Shore; P E Fielding
Journal:  Biochim Biophys Acta       Date:  1972-08-11

3.  Enzymatic determination of total serum cholesterol.

Authors:  C C Allain; L S Poon; C S Chan; W Richmond; P C Fu
Journal:  Clin Chem       Date:  1974-04       Impact factor: 8.327

4.  Effects of ultracentrifugation on the human serum high-density (1.063 less than p less than 1.21 g/ml) lipoprotein.

Authors:  A Scanu; J L Granda
Journal:  Biochemistry       Date:  1966-02       Impact factor: 3.162

5.  Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism.

Authors:  G Salen
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

6.  Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system.

Authors:  J H Menkes; J R Schimschock; P D Swanson
Journal:  Arch Neurol       Date:  1968-07

7.  Fatty acid composition of human plasma lipoprotein fractions.

Authors:  D S Goodman; T Shiratori
Journal:  J Lipid Res       Date:  1964-07       Impact factor: 5.922

8.  Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: structure of low and high density lipoproteins as revealed by elctron microscopy.

Authors:  T Forte; K R Norum; J A Glomset; A V Nichols
Journal:  J Clin Invest       Date:  1971-05       Impact factor: 14.808

9.  The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.

Authors:  G Salen; S M Grundy
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  A biochemical abnormality in cerebrotendinous xanthomatosis. Impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain.

Authors:  T Setoguchi; G Salen; G S Tint; E H Mosbach
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

View more
  4 in total

1.  Cerebrotendinous xanthomatosis in the Israeli Druze: molecular genetics and phenotypic characteristics.

Authors:  E Leitersdorf; R Safadi; V Meiner; A Reshef; I Björkhem; Y Friedlander; S Morkos; V M Berginer
Journal:  Am J Hum Genet       Date:  1994-11       Impact factor: 11.025

2.  A case of cerebrotendinous xanthomatosis. II: The sterol content of a cataractous lens.

Authors:  P McKenna; S J Morgan; R C Bosanquet; M F Laker
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

3.  Nucleotide sequence and the encoded amino acids of human apolipoprotein A-I mRNA.

Authors:  S W Law; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

Review 4.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.